Citius Pharmaceuticals Announces FDA Acceptance Of BLA Resubmission of LYMPHIR For Treatment Of Adults With Relapsed Or Refractory Cutaneous T-Cell Lymphoma
Portfolio Pulse from Benzinga Newsdesk
Citius Pharmaceuticals announced that the FDA has accepted the BLA resubmission for LYMPHIR, a treatment for adults with relapsed or refractory cutaneous T-cell lymphoma. The FDA has set a PDUFA target action date of August 13, 2024.
March 18, 2024 | 12:37 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Citius Pharmaceuticals' LYMPHIR BLA resubmission accepted by FDA, with a PDUFA date set for August 13, 2024, for treating cutaneous T-cell lymphoma.
The acceptance of the BLA resubmission by the FDA is a significant positive development for Citius Pharmaceuticals, indicating progress towards the potential approval of LYMPHIR. This news is likely to be viewed positively by investors, as it moves the company closer to bringing a new treatment to market, which could significantly impact its revenue and growth prospects. The setting of a PDUFA date provides a clear timeline for the next regulatory milestone.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100